Denise de Wijs on Thursday announced that she has been promoted to Finance Director at Teva Pharmaceuticals’ Malta operations, and will start working in her new position in April.
Prior to this, she served as Director of Accounting at the company’s operations in Benelux for almost four years. She was also Associate Director of Accounting and Financial Reporting at Teva Pharmaceuticals for 10 months.
For more than 15 years, Ms De Wijs worked as Audit Senior Manager at professional services firm PwC’s office in the Netherlands, during which time she managed the audits of statutory accounts, numerous special projects such as acquisitions, public debt and listing transactions, and was also Group Audit Senior Manager of large multinational companies. While working at PwC, she also served as Audit Manager at its Canada office, and also as Group Reporting Specialist at energy and petrochemical company Shell.
She conducted a postgraduate study to become a registered accountant from Vrije Universiteit Amsterdam and higher education in accountancy from The Hague University of Applied Sciences.
Founded in 1901, Teva Pharmaceuticals is a medicine developer and producer, that has a portfolio of 3,500 products. It has a presence in multiple countries, including a production site in Żejtun, Malta. The Malta site’s roots trace back to 1976, and became part of Teva Pharmaceuticals in 2016.
Featured Image:
Teva Malta's Żejtun site / Teva Malta / Facebook
With expertise in corporate law, energy law, and aviation law, he brings a wealth of experience to the firm.
As hybrid work becomes the norm, CEOs must rethink how they allocate their time.
The shake-up in the company’s Board of Directors follows the acquisition by the UK-based Frasers Group of a non-controlling interest ...
The bank is obliged to identify a candidate with the necessary time, commitment, knowledge, qualifications and experience.